Transient Anti‐Drug Antibodies and Their Impact on Markers of Inflammation: Longitudinal Data From a 7‐Year Study of Certolizumab Pegol in Crohn's Disease Patients: 1830. (October 2015) - Sandborn, William J.; Kosutic, Gordana; Parker, Gerry; Oliver, Ruth; Coarse, Jason; Spearman, Marshall; Khanna, Reena; Feagan, Brian